DNA methylation contributes to the regulation of sclerostin expression in human osteocytes

Journal of Bone and Mineral Research

Volumn 27, Issue 4, 2012, Pages 926-937

  Delgado Calle, Jesús ^a   Sañudo, Carolina ^a   Bolado, Alfonso ^a   Fernández, Agustín F ^b   Arozamena, Jana ^a   Pascual Carra, María A ^c   Rodriguez Rey, José C ^a   Fraga, Mario F ^b,d   Bonewald, Lynda ^e   Riancho, José A ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

DNA methylation; Osteoblasts; osteocytes; promoter; sclerostin

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; DNA; SCLEROSTIN;

ARTICLE; CELL LINE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; EXON; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; OSTEOBLAST; OSTEOCYTE; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; UPREGULATION;

AZACITIDINE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEINS; CLONING, MOLECULAR; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC MARKERS; HEK293 CELLS; HUMANS; NUCLEAR PROTEINS; OSTEOBLASTS; OSTEOCYTES; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SEQUENCE DELETION;

EID: 84858713611     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1491     Document Type: Article

References (54)

1. van Bezooijen RL, Roelen BA, Visser A, Wee-Pals L, de WE, Karperien M, Hamersma H, Papapoulos SE, ten DP, Lowik CW,. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004; 199 (6): 805-14. (Pubitemid 38375200)
2. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA,. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22 (23): 6267-76. (Pubitemid 37522584)
3. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J,. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19 (13): 1842-4. (Pubitemid 41598769)
4. ten Dijke P, Krause C, de Gorter DJ, Lowik CW, van Bezooijen RL,. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am. 2008; 90 (Suppl 1): 31-5. (Pubitemid 351329118)
5. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D,. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280 (20): 19883-7. (Pubitemid 41379516)
6. Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, Bouwmeester T, Schirle M, Bueno-Lozano M, Fuentes FJ, Itin PH, Boudin E, de Freitas F, Jennes K, Brannetti B, Charara N, Ebersbach H, Geisse S, Lu CX, Bauer A, Van Hul W, Kneissel M,. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011; 286: 19489-500.
7. Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA,. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone. 2004; 35 (4): 828-35. (Pubitemid 39349213)
8. Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, Zelenchuk L, Evdokiou A, Findlay DM,. Sclerostin is a locally acting regulator of late-osteoblast/pre-osteocyte differentiation and regulates mineralization through a MEPE-ASARM dependent mechanism. J Bone Miner Res. 2011; 26 (7): 1425-36.
9. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den EJ, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W,. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10 (5): 537-43. (Pubitemid 32184286)
10. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J,. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68 (3): 577-89. (Pubitemid 32202753)
11. Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P,. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res. 2010; 25 (11): 2412-8.
12. Padhi D, Jang G, Stouch B, Fang L, Posvar E,. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26 (1): 19-26.
13. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ,. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE. 2011; 6 (10): e25900.
14. Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, Keller H,. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res. 2007; 22 (12): 1957-67. (Pubitemid 351229312)
15. Keller H, Kneissel M,. SOST is a target gene for PTH in bone. Bone. 2005; 37 (2): 148-58. (Pubitemid 40962421)
16. Kamiya N, Kobayashi T, Mochida Y, Yu PB, Yamauchi M, Kronenberg HM, Mishina Y,. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res. 2010; 25 (2): 200-10.
17. Genetos DC, Toupadakis CA, Raheja LF, Wong A, Papanicolaou SE, Fyhrie DP, Loots GG, Yellowley CE,. Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J Cell Biochem. 2010; 110 (2): 457-67.
18. Papanicolaou SE, Phipps RJ, Fyhrie DP, Genetos DC,. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. Biorheology. 2009; 46 (5): 389-99.
19. Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR, Fazzalari NL, Evdokiou A, Atkins GJ,. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res. 2009; 24 (8): 1434-49.
20. Genetos DC, Yellowley CE, Loots GG,. Prostaglandin E(2) signals through PTGER2 to regulate sclerostin expression. PLoS ONE. 2011; 6 (3): e17772.
21. Bonnet N, Standley KN, Bianchi EN, Stadelmann V, Foti M, Conway SJ, Ferrari SL,. The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity. J Biol Chem. 2009; 284 (51): 35939-50.
22. Cohen-Kfir E, Artsi H, Levin A, Abramowitz E, Bajayo A, Gurt I, Zhong L, D'Urso A, Toiber D, Mostoslavsky R, Dresner-Pollak R,. Sirt1 is a regulator of bone mass and a repressor of sost encoding for sclerostin: a bone formation inhibitor. Endocrinology. 2011; 152 (12): 4514-24.
23. Boukhechba F, Balaguer T, Michiels JF, Ackermann K, Quincey D, Bouler JM, Pyerin W, Carle GF, Rochet N,. Human primary osteocyte differentiation in a 3D culture system. J Bone Miner Res. 2009; 24 (11): 1927-35.
24. Berdasco M, Esteller M,. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010; 19 (5): 698-711.
25. Dansranjavin T, Krehl S, Mueller T, Mueller LP, Schmoll HJ, Dammann RH,. The role of promoter CpG methylation in the epigenetic control of stem cell related genes during differentiation. Cell Cycle. 2009; 8 (6): 916-24.
26. Miranda TB, Jones PA,. DNA methylation: the nuts and bolts of repression. J Cell Physiol. 2007; 213 (2): 384-90. (Pubitemid 47509717)
27. Kitazawa R, Kitazawa S,. Methylation status of a single CpG locus 3 bases upstream of TATA-box of receptor activator of nuclear factor-kappaB ligand (RANKL) gene promoter modulates cell- and tissue-specific RANKL expression and osteoclastogenesis. Mol Endocrinol. 2007; 21 (1): 148-58. (Pubitemid 46041696)
28. Lu TY, Kao CF, Lin CT, Huang DY, Chiu CY, Huang YS, Wu HC,. DNA methylation and histone modification regulate silencing of OPG during tumor progression. J Cell Biochem. 2009; 108 (1): 315-25.
29. El Serafi AT, Oreffo RO, Roach HI,. Epigenetic modifiers influence lineage commitment of human bone marrow stromal cells: differential effects of 5-aza-deoxycytidine and trichostatin A. Differentiation. 2011; 81 (1): 35-41.
30. Arnsdorf EJ, Tummala P, Castillo AB, Zhang F, Jacobs CR,. The epigenetic mechanism of mechanically induced osteogenic differentiation. J Biomech. 2010; 43 (15): 2881-6.
31. Bonewald LF,. The amazing osteocyte. J Bone Miner Res. 2011; 26 (2): 229-38.
32. Dallas SL, Bonewald LF,. Dynamics of the transition from osteoblast to osteocyte. Ann N Y Acad Sci. 2010; 1192: 437-43.
33. Jonsson KB, Frost A, Nilsson O, Ljunghall S, Ljunggren O,. Three isolation techniques for primary culture of human osteoblast-like cells: a comparison. Acta Orthop Scand. 1999; 70 (4): 365-73. (Pubitemid 29497473)
34. Hernandez JL, Garces CM, Sumillera M, Fernandez-Aldasoro EV, Garcia-Ibarbia C, Ortiz-Gomez JA, Arozamena J, Alonso MA, Riancho JA,. Aromatase expression in osteoarthritic and osteoporotic bone. Arthritis Rheum. 2008; 58 (6): 1696-700. (Pubitemid 351847522)
35. Sasaki M, Anast J, Bassett W, Kawakami T, Sakuragi N, Dahiya R,. Bisulfite conversion-specific and methylation-specific PCR: a sensitive technique for accurate evaluation of CpG methylation. Biochem Biophys Res Commun. 2003; 309 (2): 305-9. (Pubitemid 37025892)
36. Tost J, Dunker J, Gut IG,. Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques. 2003; 35 (1): 152-6. (Pubitemid 36828725)
37. Delgado-Calle J, Arozamena J, Garcia-Renedo R, Garcia-Ibarbia C, Pascual-Carra MA, Gonzalez-Macias J, Riancho JA,. Osteocyte deficiency in hip fractures. Calcif Tissue Int. 2011; 89 (4): 327-34.
38. Vaissiere T, Cuenin C, Paliwal A, Vineis P, Hoek G, Krzyzanowski M, Airoldi L, Dunning A, Garte S, Hainaut P, Malaveille C, Overvad K, Clavel-Chapelon F, Linseisen J, Boeing H, Trichopoulou A, Trichopoulos D, Kaladidi A, Palli D, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, Kumle M, Gonzalez CA, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quiros JR, Berglund G, Janzon L, Jarvholm B, Day NE, Key TJ, Saracci R, Kaaks R, Riboli E, Hainaut P, Herceg Z,. Quantitative analysis of DNA methylation after whole bisulfitome amplification of a minute amount of DNA from body fluids. Epigenetics. 2009; 4 (4): 221-30.
39. Klug M, Rehli M,. Functional analysis of promoter CpG methylation using a CpG-free luciferase reporter vector. Epigenetics. 2006; 1 (3): 127-30.
40. Mozas P, Galetto R, Albajar M, Ros E, Pocovi M, Rodriguez-Rey JC,. A mutation (-49C>T) in the promoter of the low density lipoprotein receptor gene associated with familial hypercholesterolemia. J Lipid Res. 2002; 43 (1): 13-8. (Pubitemid 34117212)
41. Callinan PA, Feinberg AP,. The emerging science of epigenomics. Hum Mol Genet. 2006; 15 (Spec No 1): R95-101.
42. Dierkes C, Kreisel M, Schulz A, Steinmeyer J, Wolff JC, Fink L,. Catabolic properties of microdissected human endosteal bone lining cells. Calcif Tissue Int. 2009; 84 (2): 146-55.
43. Delgado-Calle J, Sanudo C, Sanchez-Verde L, Garcia-Renedo RJ, Arozamena J, Riancho JA,. Epigenetic regulation of alkaline phosphatase in human cells of the osteoblastic lineage. Bone. 2011; 49 (4): 830-8.
44. Weber M, Schubeler D,. Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Curr Opin Cell Biol. 2007; 19 (3): 273-80. (Pubitemid 46899512)
45. Patra SK, Patra A, Rizzi F, Ghosh TC, Bettuzzi S,. Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development. Cancer Metastasis Rev. 2008; 27 (2): 315-34.
46. Jang HJ, Choi JW, Kim YM, Shin SS, Lee K, Han JY,. Reactivation of transgene expression by alleviating CpG methylation of the Rous sarcoma virus promoter in transgenic quail cells. Mol Biotechnol. 2011; 49: 222-8.
47. Petkova TD, Seigel GM, Otteson DC,. A role for DNA methylation in regulation of EphA5 receptor expression in the mouse retina. Vision Res. 2011; 51 (2): 260-8.
48. Takai E, Mauck RL, Hung CT, Guo XE,. Osteocyte viability and regulation of osteoblast function in a 3D trabecular bone explant under dynamic hydrostatic pressure. J Bone Miner Res. 2004; 19 (9): 1403-10. (Pubitemid 41094341)
49. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM,. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005; 15 (7): 928-35. (Pubitemid 40994212)
50. Sevetson B, Taylor S, Pan Y,. Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST). J Biol Chem. 2004; 279 (14): 13849-58. (Pubitemid 38468917)
51. Klose RJ, Bird AP,. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006; 31 (2): 89-97. (Pubitemid 43221841)
52. Kim MS, Kondo T, Takada I, Youn MY, Yamamoto Y, Takahashi S, Matsumoto T, Fujiyama S, Shirode Y, Yamaoka I, Kitagawa H, Takeyama K, Shibuya H, Ohtake F, Kato S,. DNA demethylation in hormone-induced transcriptional derepression. Nature. 2009; 461 (7266): 1007-12.
53. Pan Q, Wu Y, Lin T, Yao H, Yang Z, Gao G, Song E, Shen H,. Bone morphogenetic protein-2 induces chromatin remodeling and modification at the proximal promoter of Sox9 gene. Biochem Biophys Res Commun. 2009; 379 (2): 356-61.
54. Atkins GJ, Welldon KJ, Halbout P, Findlay DM,. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int. 2009; 20 (4): 653-64.